Deutsch English Français

Contact

EP3009423

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...

News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...

Extract from the Register of European Patents

EP About this file: EP3009423

*EP3009423 - CRYSTALLINE FORMS OF [R-(R,R)]-2-(4-FLUOROPHENYL)-BETA, DELTA-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-PHENYLAMINO)CARBONYL]-1H-PYRROLE-1-HEPTANOIC ACID CALCIUM SALT (2:1) (ATORVASTATIN)* [Right-click to bookmark this link]
Status	The application is deemed to be withdrawn Status updated on 05.04.2019 Database last updated on 03.06.2024
Former	Examination is in progress Status updated on 18.05.2018
Former	Request for examination was made Status updated on 07.07.2017
Most recent event Tooltip	05.04.2019	Application deemed to be withdrawn	published on 08.05.2019 [2019/19]
Applicant(s)	For all designated states Warner-Lambert Company LLC 235 East 42nd Street New York, NY 10017 / US
	[2016/16]
Inventor(s)	01 / BYRN, Stephen Robert 824 Barlow Street West Lafayette, IN 47906 / US
	02 / COATES, David Andrew 2435 Neil Armstrong Dr., Apt 24 West Lafayette, IN 47906 / US
	03 / GUSHURST, Karen Sue 807 Columbia Street Lafayette, IN 47901 / US
	04 / MORRISON, Henry Grant, II 2304 Osage Ct., Apt. 70 Lafayette, IN 47909 / US
	05 / PARK, Aeri 1717 Southworth Branch Dr. West Lafayette, IN 47906 / US
	06 / VLAHOVA, Petinka Ivanova 4702 Admirals Pointe Dr. Lafayette, IN 47909 / US
	07 / LI, Zheng J. Pfizer Global Research and Dev. Eastern Point Road Groton, IN 06340 / US
	08 / KRZYZANIAK, J. F. Pfizer Global Research and Dev. Eastern Point Road Groton, IN 06340 / US
	[2016/16]
Representative(s)	Schön, Christoph Dr. Schön, Neymeyr & Partner mbB Bavariaring 26 80336 München / DE
	[2016/16]
Application number, filing date	15192682.1	21.05.2002
	[2016/16]
Priority number, date	US20010302049P	29.06.2001 Original published format: US 302049 P
	[2016/16]
Filing language	EN
Procedural language	EN
Publication	Type:	A2 Application without search report
	No.:	EP3009423
	Date:	20.04.2016
	Language:	EN
	[2016/16]
	Type:	A3 Search report
	No.:	EP3009423
	Date:	28.12.2016
	Language:	EN
	[2016/52]
Former [2016/34]	Type:	A3 Search report
	No.:	EP3009423
	Date:
	Status:	(deleted)
	[2016/34]
	[2016/52]
Search report(s)	(Supplementary) European search report - dispatched on:	EP	30.11.2016
Classification	IPC:	C07D207/34, A61K31/401	[2016/16]
	CPC:	A61K31/401 (EP,US); C07D207/34 (EP,KR,US); A61P19/10 (EP); A61P25/28 (EP); A61P3/06 (EP)
Designated contracting states	AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, TR [2017/32]
Former [2016/16]	AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, TR
Extension states	AL	03.11.2015
	LT	03.11.2015
	LV	03.11.2015
	MK	03.11.2015
	RO	03.11.2015
	SI	03.11.2015
Title	German:	KRISTALLINE FORMEN DES CALCIUMSALZES (2:1) VON [R-(R,R)]-2-(4-FLUORPHENYL)-BETA, DELTA -DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-(PHENYLAMINO)CARBONYL]-1H-PYRROL-1-HEPTANSÄURE (ATORVASTATIN)	[2016/16]
	English:	CRYSTALLINE FORMS OF [R-(R,R)]-2-(4-FLUOROPHENYL)-BETA, DELTA-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-PHENYLAMINO)CARBONYL]-1H-PYRROLE-1-HEPTANOIC ACID CALCIUM SALT (2:1) (ATORVASTATIN)	[2016/16]
	French:	FORMES CRISTALLINES DE SEL HEMICALCIQUE (2:1) D'ACIDE [R-(R,R)] -2-(4-FLUOROPHENYL)-BETA,DELTA-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-(PHENYLAMINO)CARBONYL -1H-PYRROLE-1-HEPTANOIQUE (ATORVASTATINE)	[2016/16]
Examination procedure	03.11.2015	Date on which the examining division has become responsible
	28.06.2017	Amendment by applicant (claims and/or description)
	28.06.2017	Examination requested [2017/32]
	17.05.2018	Despatch of a communication from the examining division (Time limit: M06)
	28.11.2018	Application deemed to be withdrawn, date of legal effect [2019/19]
	04.01.2019	Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time [2019/19]
Parent application(s) Tooltip	EP02727946.2 / EP1423364
Fees paid	Renewal fee
	03.11.2015	Renewal fee patent year 03
	03.11.2015	Renewal fee patent year 04
	03.11.2015	Renewal fee patent year 05
	03.11.2015	Renewal fee patent year 06
	03.11.2015	Renewal fee patent year 07
	03.11.2015	Renewal fee patent year 08
	03.11.2015	Renewal fee patent year 09
	03.11.2015	Renewal fee patent year 10
	03.11.2015	Renewal fee patent year 11
	03.11.2015	Renewal fee patent year 12
	03.11.2015	Renewal fee patent year 13
	03.11.2015	Renewal fee patent year 14
	30.03.2016	Renewal fee patent year 15
	08.05.2017	Renewal fee patent year 16
	07.05.2018	Renewal fee patent year 17
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:	Search	[XI]WO9703959 (WARNER LAMBERT CO [US], et al) [X] 1,15 * Form II;; figures 2, 5; examples 1, 2; claim - * [I] 7;
		[XI]WO0136384 (TEVA PHARMA [IL], et al) [X] 7 * page 10-lines 16-19; example 6; page 2, line 16 - page 4, line 17; figure -; example -; claim - * [I] 1,15;
		[E]WO0241834 (TEVA PHARMA [IL], et al) [E] 1,7,15* page 5, paragraph 3; figure -; claim - *;
		[E]WO0243732 (TEVA PHARMA [IL], et al) [E] 1,7,15 * the whole document *;
		[E]WO02051804 (CIBA SC HOLDING AG [CH], et al) [E] 1,7,15 * the whole document *
	by applicant	US4681893
		US5003080
		US5097045
		US5103024
		US5124482
		US5149837
		US5155251
		US5216174
		US5245047
		US5248793
		US5273995
		US5280126
		US5298627
		US5342952
		US5397792
		US5446054
		US5470981
		US5489690
		US5489691
		US5510488
		US5686104
		US5969156
		US5998633
		US6087511
		US6121461
		US6126971
		WO0136384
		- CHEN ET AL., J PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, (2001), vol. 26, page 63
		- WELLS J.I.; AULTON M.E., Pharmaceutics. The Science of Dosage Form Design. Reformulation, CHURCHILL LIVINGSTONE, (1988), vol. 13, page 237
		- HIESTAND H; SMITH D., "Indices of Tableting Performance", POWDER TECHNOLOGY, (1984), vol. 38, pages 145 - 159

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.1.24; 34p